Literature DB >> 31699497

Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response.

Sergio Linares-Fernández1, Céline Lacroix1, Jean-Yves Exposito1, Bernard Verrier2.   

Abstract

mRNA vaccine platforms present numerous advantages, such as versatility, rapid production, and induction of cellular and humoral responses. Moreover, mRNAs have inherent adjuvant properties due to their complex interaction with pattern recognition receptors (PRRs). This recognition can be either beneficial in activating antigen-presenting cells (APCs) or detrimental by indirectly blocking mRNA translation. To decipher this Janus effect, we describe the different innate response mechanisms triggered by mRNA molecules and how each element from the 5' cap to the poly-A tail interferes with innate/adaptive immune responses. Then, we emphasize the importance of some critical steps such as production, purification, and formulation as key events to further improve the quality of immune responses and balance innate and adaptive immunity.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  adaptive immunity; innate immunity; mRNA design; mRNA vaccines

Mesh:

Substances:

Year:  2019        PMID: 31699497     DOI: 10.1016/j.molmed.2019.10.002

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  68 in total

1.  Polylactide-Based Reactive Micelles as a Robust Platform for mRNA Delivery.

Authors:  Céline Lacroix; Almudena Humanes; Céline Coiffier; Didier Gigmes; Bernard Verrier; Thomas Trimaille
Journal:  Pharm Res       Date:  2020-01-08       Impact factor: 4.200

Review 2.  Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies.

Authors:  Lanying Du; Yang Yang; Xiujuan Zhang; Fang Li
Journal:  Nanoscale       Date:  2022-01-27       Impact factor: 7.790

Review 3.  Novel approaches for vaccine development.

Authors:  Makda S Gebre; Luis A Brito; Lisa H Tostanoski; Darin K Edwards; Andrea Carfi; Dan H Barouch
Journal:  Cell       Date:  2021-03-18       Impact factor: 41.582

4.  Corticosteroids and cellulose purification improve, respectively, the in vivo translation and vaccination efficacy of sa-mRNAs.

Authors:  Zifu Zhong; Séan McCafferty; Lisa Opsomer; Haixiu Wang; Hanne Huysmans; Joyca De Temmerman; Stefan Lienenklaus; João Paulo Portela Catani; Francis Combes; Niek N Sanders
Journal:  Mol Ther       Date:  2021-01-21       Impact factor: 11.454

Review 5.  COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy.

Authors:  Giuseppe Novelli; Michela Biancolella; Ruty Mehrian-Shai; Vito Luigi Colona; Anderson F Brito; Nathan D Grubaugh; Vasilis Vasiliou; Lucio Luzzatto; Juergen K V Reichardt
Journal:  Hum Genomics       Date:  2021-05-10       Impact factor: 4.639

6.  Chemo-Enzymatic Modification of the 5' Cap Maintains Translation and Increases Immunogenic Properties of mRNA.

Authors:  Melissa van Dülmen; Nils Muthmann; Andrea Rentmeister
Journal:  Angew Chem Int Ed Engl       Date:  2021-05-06       Impact factor: 15.336

Review 7.  mRNA vaccines manufacturing: Challenges and bottlenecks.

Authors:  Sara Sousa Rosa; Duarte M F Prazeres; Ana M Azevedo; Marco P C Marques
Journal:  Vaccine       Date:  2021-03-24       Impact factor: 4.169

Review 8.  A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics.

Authors:  Lauren Forchette; William Sebastian; Tuoen Liu
Journal:  Curr Med Sci       Date:  2021-07-09

Review 9.  From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Manojit Bhattacharya; Sang-Soo Lee
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

Review 10.  Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2.

Authors:  Javier T Granados-Riveron; Guillermo Aquino-Jarquin
Journal:  Biomed Pharmacother       Date:  2021-07-23       Impact factor: 6.529

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.